Acute kidney injury is a common complication in cancer patients, and clinicians should be familiar with the processes that cause it.
The approval of PARP inhibitors has caused a paradigm shift in ovarian cancer management and a challenge for clinicians, who must decide how best to use these agents in individualized treatment.
The way in which serious news is discussed significantly affects many outcomes and aspects of patient care. It is important to consider many factors, including those related to patient diversity, such as cultural and family background; language barriers; socioeconomic factors; and health literacy.
In this interview, we discuss a study of sex differences in the tolerability of anti–programmed death 1 immunotherapy among patients with metastatic melanoma.
Next-generation sequencing may prove to be a useful tool in the identification of co-mutations associated with resistance, an MD Anderson study suggests.
A pilot protocol developed at Memorial Sloan Kettering Cancer Center resulted in exponential increases in both influenza and pneumococcal vaccinations in the outpatient setting.
Overexpression of IKZF1 facilitates immune attack on skin cancer and other solid tumors.
A team from Children’s Healthcare of Atlanta reports unexpected factors determining which adolescents participated in sperm banking.
Three and 6 months after undergoing the psychotherapeutic intervention Managing Cancer and Living Meaningfully (CALM), participants reported less-severe depressive symptoms.
More than 20% of patients with non–clear cell RCC had a germline mutation, and half of this group could benefit from direct systemic therapy.
Quit rates reported by a smoking-cessation program at Duke Cancer Center increased from 17% to 34% in the 2 years since it was implemented.
A small study has found that men with cancer were less likely than women to prefer palliative care if informed that continued treatment would not be helpful.
While over half of survivors had heard of metabolic syndrome, in one-third with the condition, fewer than 10% had been diagnosed; educational strategies may be of benefit.
The OS benefit associated with standard treatment diminished in patients older than 80 with high comorbidity scores, but other age groups fared better.
There may be prophylactic benefit from using lenalidomide, an orally bioavailable CNS-penetrating agent, combined with R-CHOP in the upfront setting.